Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting
Michèle Tameris, Virginie Rozot, Claire Imbratta, Hennie Geldenhuys, Simon C. Mendelsohn, Angelique Kany Kany Luabeya, Justin Shenje, Nicolette Tredoux, Michelle Fisher, Humphrey Mulenga, Nicole Bilek, Carly Young, Ashley Veldsman, Natasja Botes, Jelle Thole, Bernard Fritzell, Rajat Mukherjee, Ingrid Murillo Jelsbak, Esteban Rodríguez, Eugenia Puentes, Juana Doce, Dessislava Marinova, Jesús Gonzalo‐Asensio, Nacho Aguiló, Carlos Martı́n, Thomas J. Scriba, Mark Hatherill, Charmaine Abrahams, Hadn Africa, Denis Arendsen, Liezl Barnard, Yolundi Cloete, Ilse Davids, Mzwandile Erasmus, Elizabeth Filander, Yolande Gregg, Roxane Herling, Ruwiyda Jansen, Lungisa Jack, Xoliswe Kelepu, Henriette Kyepa, Thelma Leopeng, Simbarahse Mabwe, Lauren Mactavie, Lebohang Makhete, Sandisiwe Mangali, Angelique Mouton, Hlengiwe Nkambule, Julia Noble, Onke Nombida, Nambitha Nqakala, Fajwa Opperman, Rodney Raphela, Susan Rossouw, Elisma Schoeman, Constance Schreuder, Marcia Steyn, Liticia Swanepoel, Asma Toefy, Anele Tromp, Petrus Tyambethu, Habibullah Valley, Johanna Van Rooyes
Abstract
Background Safer and more effective tuberculosis (TB) vaccines than Bacille Calmette Guérin (BCG) are needed. We evaluated the safety, reactogenicity, and immunogenicity of three dose levels of the live-attenuated Mycobacterium tuberculosis ( Mtb ) vaccine, MTBVAC, compared to BCG, in South African infants. Methods Healthy, HIV-unexposed, BCG-naïve infants were randomised to receive a single intradermal dose of BCG (2.5 × 10 5 CFU, n = 24) or MTBVAC (2.5 × 10 4 , 2.5 × 10 5 , or 2.5 × 10 6 CFU, each n = 25). Safety endpoints were solicited systemic, solicited injection site, and unsolicited adverse events (AE), and serious AE (SAE). Immunogenicity was measured using interferon-γ release assay (IGRA) and whole blood intracellular cytokine staining assay. Follow-up was 12 months post-vaccination. Findings Ninety-nine infants were enrolled between 18 February 2019 and 08 March 2021. Seventy-eight infants experienced reactogenicity AE (all mild except one grade 2 erythema). Induration, swelling, and erythema were more frequent as MTBVAC dose increased. All reactogenicity events were less frequent in infants receiving MTBVAC 2.5 × 10 5 CFU compared with BCG. Twelve infants (three BCG and nine MTBVAC recipients) experienced 14 vaccine-unrelated SAE, including one death due to bronchopneumonia (MTBVAC recipient). Eight infants were treated for unconfirmed pulmonary TB (four BCG and four MTBVAC 2.5 × 10 4 CFU recipients); one BCG recipient was treated for unconfirmed TB meningitis. MTBVAC was immunogenic at all 3 doses, inducing predominantly Th1-cytokine-expressing CD4 T cells, which peaked at Day 56. The 2.5 × 10 5 and 2.5 × 10 6 CFU MTBVAC doses induced similar response magnitudes and were more immunogenic than BCG. Day 56 IGRA conversion was observed in 61 (87.4%) infants receiving any MTBVAC dose, but only 28 (42.4%) remained positive by Day 365. Interpretation MTBVAC appeared safe, well-tolerated, and immunogenic at doses between 2.5 × 10 4 and 2.5 × 10 6 CFU in South African infants. The 2.5 × 10 5 CFU MTBVAC dose, being less reactogenic and more immunogenic than BCG, was selected for a multi-centre, phase 3 trial. Funding This trial was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP).